Low leptin concentration has been shown to be associated with central sleep apnea in heart failure patients. We hypothesized that low leptin concentration predicts central sleep apnea. Consecutive ambulatory New York Heart Association (NYHA) classes I-IV heart failure patients were studied prospectively, including measurement of serum leptin, echocardiography and polysomnography. Sleep apnea was defined by type (central/mixed/obstructive) and by apnea-hypopnea index ≥5 by polysomnography. Subjects were divided into four groups by polysomnography: (1) central sleep apnea, (2) mixed apnea, (3) no apnea and (4) obstructive sleep apnea. Fifty-six subjects were included. Eighteen subjects were diagnosed with central sleep apnea, 15 with mixed apnea, 12 with obstructive apnea and 11 with no sleep apnea. Leptin concentration was significantly lower in central sleep apnea compared to obstructive apnea (8 AE 10.7 ng mL À1 versus 19.7 AE 14.7 ng mL À1 , P ˂ 0.01) or no sleep apnea (8 AE 10.7 ng mL À1 versus 17.1 AE 8.4 ng mL À1 , P ˂ 0.01). Logistic regression showed leptin to be associated independently with central sleep apnea [odds ratio (OR): 0.19; 95% confidence interval (CI): 0.06-0.62; area under the curve (AUC): 0.80, P < 0.01]. For the detection of central sleep apnea, a cut-off value for leptin concentration 5 ng mL À1 yielded a sensitivity of 50% and specificity of 89%. In conclusion, a low leptin concentration may have utility for the screening of heart failure patients for central sleep apnea.
IN TROD UCTI ON
In heart failure (HF) patients, sleep-disordered breathing is highly prevalent (Arzt et al., 2016) , and associated with nocturnal hypoxaemia, an independent predictor of mortality . Central sleep apnea (CSA), a form of sleep-disordered breathing, is frequent (up to 40% in case series) and has been shown to be related to increased mortality (Arzt et al., 2016) and hospital readmission rates (Khayat et al., 2012) . Although therapy is available (Arzt et al., 2007) , there is a need for improved screening strategies to identify patients most appropriate for referral for definitive diagnosis by polysomnography (PSG).
Biomarkers that screen effectively for CSA would be useful, as the tools available are either not sufficiently sensitive or specific (S eri es et al., 2005) . Recently, both brain (BNP) and atrial natriuretic peptide (Calvin et al., 2011) and leptin (Cundrle et al., 2014) were shown to be associated with increased likelihood of CSA. Natriuretic peptides are elevated in HF patients with CSA and have been proposed as a potential screening tool, although in a small and highly selected cohort (Calvin et al., 2011) . Leptin concentration has been shown to be low and correlated inversely with ventilatory drive in HF patients with CSA (Cundrle et al., 2014) . However, whether leptin concentrations may be useful for identification of patients with CSA is not known.
We hypothesized that in HF patients low leptin concentrations predicts CSA. Accordingly, the aim of this study was to evaluate leptin concentrations in HF patients with ª 2017 European Sleep Research Society and without CSA, as demonstrated by complete overnight PSG.
METHODS

Subject selection
Subjects were ambulatory outpatients with symptomatic HF with left ventricular ejection fraction (LVEF) ≤35% with stable symptoms [New York Heart Association (NYHA) classes I-IV] and on optimal pharmacotherapy for at least 3 months. Exclusion criteria were known sleep apnea and unstable symptoms. All participants gave written informed consent. This study was conducted in accordance with the declaration of Helsinki and approved by the Mayo Clinic Institutional Review Board.
Polysomnography
All PSGs were recorded digitally on either a Network Concepts Incorporated (Middleton, WI, USA) or an E-Series (Compumedics, Abbotsford, VIC, Australia) digital PSG acquisition system. All PSGs were scored for sleep stages and disordered breathing events, according to American Academy of Sleep Medicine (AASM) scoring guidelines (Iber et al., 2007) . Sleep apnea was defined by the type (central/ mixed/obstructive) and by the apnea-hypopnea index (AHI) ≥5 by PSG. Accordingly, subjects were divided into four groups: (1) CSA, (2) mixed apnea, (3) no apnea and (4) obstructive sleep apnea.
Leptin and brain natriuretic peptide
Venous blood was collected in the morning after an overnight fast on the same day as PSG. Measurement of plasma leptin was performed by radioimmunoassay (Linco Research Inc., St Charles, MO, USA). Measurement of BNP was evaluated by Shionogi immunoradiometric assay (Shionogi & Co, Ltd, Osaka, Japan).
Statistical analysis
Tests used included the Shapiro-Wilk test, one-way analysis of variance, Chi-square test, unpaired t-test or Mann-Whitney U-test, Spearman's rank test, logistic and multiple regression [controlled for potential confounders as age, gender and body mass index (BMI)] and decision statistics (2 9 2 tables). Logarithmic transformation was performed for variables with non-normal distribution. The results were expressed as odds ratios (OR) with 95% confidence intervals (CI), mean AE standard deviation (SD) or median [interquartile range (IQR)] P < 0.05 was considered statistically significant. For comparison, ORs for continuous variables (leptin and BNP) are presented per 1 SD after transformation. Statistical analyses were performed using Statistica version 12.0 (Prague, Czech Republic) and SAS version 9.3 (Cary, NC, USA).
RESULTS
Fifty-six HF subjects were included; subject characteristics are shown in Table 1 . Eighteen subjects were diagnosed with CSA, 15 with mixed sleep apnea, 12 with obstructive sleep apnea and 11 with no sleep-disordered breathing (AHI < 5).
Subgroup comparison is shown in (95% CI: 2-34; P < 0.01). A leptin concentration cutoff of 5 ng mL À1 yielded a sensitivity of 50% and specificity of 89%
for detection of CSA (Table 3 ). Multiple regression adjusted for age, gender and BMI showed leptin to be associated independently inversely with BNP (b = À0.72; F = 6.9; P < 0.01). There was a correlation of leptin concentration and BMI (r = 0.58; P < 0.01).
DISCUSSION
The major finding of this study is that in unselected HF patients low leptin concentration is the only predictor for CSA, as demonstrated by logistic regression analysis. BNP concentration was higher in HF patients with CSA, although there was no significant association of BNP and CSA. The finding of low leptin concentration as the only independent predictor for CSA is in agreement with our previous report demonstrating low leptin concentration in patients with CSA (Cundrle et al., 2014) . A possible pathophysiological link between CSA and leptin may explain the observed association (Cundrle et al., 2014) . In our patients, leptin was also associated significantly inversely with BNP, which is consistent with a possible counter-regulatory mechanism for these hormones (Fain et al., 2003; Yuan et al., (Ruhl et al., 2007) . In our study, BNP concentration was higher in patients with CSA, in agreement with previous studies (Calvin et al., 2011; Carmona-Bernal et al., 2005) . Carmona-Bernal et al. (2005) showed in a group of chronic HF patients that BNP predicted CSA with an optimal cutoff value of 116 pg mL À1 (AUC: 0.79), which yielded sensitivity of 62% and specificity of 92% for CSA prediction (Carmona-Bernal et al., 2005) . Furthermore, BNP was also shown to predict CSA in a study by Calvin et al. (2011) , with an optimal BNP cut-off of 210 pg mL À1 (AUC: 0.73), which yielded a sensitivity of 83% and specificity of 56% for the detection of CSA (Calvin et al., 2011) . In contrast to these previous findings, in the cohort described herein logistic regression (age, gender and BMI adjusted) failed to show a significant BNP and CSA association, suggesting that BNP could not be used reliably for CSA detection in HF patients. In both the previous studies, highly selected cohorts involving only patients with either CSA or with no sleep apnea were compared (Calvin et al., 2011; Carmona-Bernal et al., 2005) . The exclusion of patients with other types of sleep apnea may limit the generalizability of these previously reported findings, and may explain the lack of association of BNP and CSA in our unselected cohort. Biomarkers that screen effectively for CSA may be useful, as CSA is associated with increased mortality (Arzt et al., 2016; Oldenburg et al., 2016) and higher hospital readmission rates (Khayat et al., 2012) . In our study, a leptin cutoff of 5 ng mL À1 yielded a sensitivity of 50% and specificity of 89%
for detection of CSA. The high specificity (low false positive rate) is of interest (suggesting leptin concentration as an initial triage test), as the definitive test (PSG) is expensive, time-consuming, uncomfortable for some patients and not readily available in all countries. Importantly, all our CSA subjects had AHI > 15, suggesting that low leptin concentration may identify individuals who may benefit from treatment (Arzt et al., 2007) . Our study had several limitations. There were more men than women in the CSA group. However, this is consistent with previous reports showing CSA to be much more prevalent in men (Sin et al., 1999) . Atrial fibrillation frequency was not reported; however, we have previously shown that atrial fibrillation is not a confounder of the leptin and CSA association (Cundrle et al., 2014) . The 2007 AASM guidelines were used for apnea scoring, although newer guidelines are available (Berry et al., 2012) , which may have caused underestimation of AHI. 
